Nautilus Biotechnology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Nautilus Biotechnology (NAUT).

Price Target Range — 4 Quarters

Analyst Consensus — 5 Analysts

3Buy

1Hold

1Sell

Consensus RatingBuy# Analysts5Avg. Consensus PT$3Upside to Avg. PT+81.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	Roth Capital	Max Masucci	Initiate	Buy	$4
Sep 9, 2026	Leerink Partners	Puneet Souda	Initiate	Outperform	$4
Feb 27, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$3→$4
Dec 5, 2024	Goldman Sachs	Matthew Sykes	Downgrade	Neutral→Sell	$2→$2
Jun 27, 2024	Guggenheim	Subbu Nambi	Initiate	Buy	$6
Jun 3, 2024	Jefferies	Tycho Peterson	Assumes	Buy→Hold	$5→$3

More with Benzinga EdgeGet Access

Analyst Ratings News

This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts initiate coverage: Buy on Nautilus ($3.50) and SpaceX ($200); Outperform on FuelCell ($24) and Butterfly ($15); Market Perform on O’Reilly ($94).

Avi Kapoor

PRO
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5

Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4

Leerink Partners analyst Puneet Souda initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Outperform rating and announces Price Target of $4.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Nautilus Biotechnology, Raises Price Target to $4

Guggenheim analyst Subbu Nambi maintains Nautilus Biotechnology (NASDAQ:NAUT) with a Buy and raises the price target from $2.5 to $4.

Benzinga Newsdesk

PRO
Goldman Sachs Downgrades Nautilus Biotechnology to Sell, Lowers Price Target to $1.75

Goldman Sachs analyst Matthew Sykes downgrades Nautilus Biotechnology (NASDAQ:NAUT) from Neutral to Sell and lowers the price target from $2.25 to $1.75.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $6

Guggenheim analyst Subbu Nambi initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $6.

Benzinga Newsdesk

Nautilus Biotechnology Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Nautilus Biotechnology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5

PRO
Leerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4

PRO
Guggenheim Maintains Buy on Nautilus Biotechnology, Raises Price Target to $4

PRO
Goldman Sachs Downgrades Nautilus Biotechnology to Sell, Lowers Price Target to $1.75

PRO
Guggenheim Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $6

People Also Watch

People Also Watch

Nautilus Biotechnology Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Nautilus Biotechnology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRORoth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5

PROLeerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4

PROGuggenheim Maintains Buy on Nautilus Biotechnology, Raises Price Target to $4

PROGoldman Sachs Downgrades Nautilus Biotechnology to Sell, Lowers Price Target to $1.75

PROGuggenheim Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $6

People Also Watch

People Also Watch

PRO
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5

PRO
Leerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4

PRO
Guggenheim Maintains Buy on Nautilus Biotechnology, Raises Price Target to $4

PRO
Goldman Sachs Downgrades Nautilus Biotechnology to Sell, Lowers Price Target to $1.75

PRO
Guggenheim Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $6